Secondly, drugs that can lower FIns and enhance insulin sensitivity, such as sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists, should be prioritized in intensive glucose-lowering therapy to mitigate adverse ventricular remodeling and its associated risk of heart failure [60, 61]. This evidence concerns the gene GLP1R and heart failure.